Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response study of ACT-334441 in systemic lupus erythematosus
2014-002984-14Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cenerimod in systemic lupus erythematosus (SLE) (4 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Pharmacodynamic endpoints. Started May 2015; status: completed.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2014-002984-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002984-14.